Cloverleaf Bio, Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-09.
Cloverleaf Bio, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 9, 2026. The filing reports $14.80M sold. Its industry group is Biotechnology. It names Austin Draycott (Executive Officer, Director), Cole Lewis (Executive Officer), Dima Kuzmin (Director) (SEC Form D, September 9, 2026).
Sell to companies like Cloverleaf Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-09 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Cloverleaf Bio, Inc.
Free to see. No signup.
More on the people and the money behind Cloverleaf Bio, Inc., from the filings we hold.
Biotechnology raises by companies based in Connecticut, filed within 90 days of this one, largest first.
Get an email when Cloverleaf Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Cloverleaf Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch Cloverleaf Bio, Inc. →Get the full cited report on Cloverleaf Bio, Inc.
What the filing shows about Cloverleaf Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cloverleaf Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $14.80M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Proceeds are available to fund general working capital requirements; no proceeds have been or are proposed to be used for payments to directors, executive officers, or promoters based specifically on the closing of this financing.
By form type: D ×1.
| Form | Filed | On EDGAR |
|---|---|---|
| D | 2026-09-09 | open |
What the filing shows about Cloverleaf Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cloverleaf Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cloverleaf Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
This is the only filing on record for this issuer, so there is no history to read yet. Incorporated in DE. Full history on sec.gov.
Austin Draycott is named as Executive Officer and Director on the Form D that Cloverleaf Bio, Inc. filed with the SEC on 9 September 2026, one of 5 people that filing names.
Cole Lewis is named as Executive Officer on the Form D that Cloverleaf Bio, Inc. filed with the SEC on 9 September 2026, one of 5 people that filing names.
Dima Kuzmin is named as Director on the Form D that Cloverleaf Bio, Inc. filed with the SEC on 9 September 2026, one of 5 people that filing names.
Christina Vorvis is named as Director on the Form D that Cloverleaf Bio, Inc. filed with the SEC on 9 September 2026, one of 5 people that filing names.
Matthias Samwer is named as Director on the Form D that Cloverleaf Bio, Inc. filed with the SEC on 9 September 2026, one of 5 people that filing names.
5 people named on the filing — 2 holding an executive role and 3 as directors only.
Named as of the 2026-09-09 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Cloverleaf Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Cloverleaf Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Cloverleaf Bio, Inc.. With no account yet, you sign up free and land on the result.
On these lists: The rest of the US raises, week of 2026-09-07 · Biotech raises, week of 2026-09-07
https://mentionfox.com/funding/cloverleaf-bio-inc-form-d-000001